Terms for how health technology assessment bodies appraise new technologies and reach funding decisions.
The National Institute for Health and Care Excellence, conducting assessment and developing guidelines for the NHS in England and, for some functions, Wales.
A recommendation category indicating a technology should be funded only within a formal research study, rather than routine clinical practice.
A treatment developed specifically for a rare disease below a specified population threshold, eligible for special regulatory designation and incentives.
A managed entry agreement, most associated with the UK, offering a discount to improve a treatment's cost-effectiveness enough to secure reimbursement.
The specific mechanisms through which patient perspectives are formally incorporated into an assessment, including expert testimony and committee representation.
The Pharmaceutical Benefits Advisory Committee, Australia's body recommending which medicines should be subsidised under the Pharmaceutical Benefits Scheme.
A structured framework specifying the Population, Intervention, Comparator, and Outcome, used to formulate a well-defined clinical or research question.
A body's formal decision to recommend a technology for funding, based on acceptable cost-effectiveness at the reviewed price.